BFRI (Biofrontera) Net Income Including Noncontrolling Interests: $-11.09 Mil (TTM As of Mar. 2026)


BFRI Biofrontera Inc BFRI
44 GF Score
Price $0.99
GF Value $0.54
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Biofrontera Net Income Including Noncontrolling Interests?

Biofrontera BFRI -3.75% 44 Net Income Including Noncontrolling Interests is $-11.09 Mil as of Mar. 2026. GuruFocus rates BFRI with a GF Score™ of 44/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Biofrontera's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2026 was $-4.75 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.09 Mil.

Biofrontera Net Income Including Noncontrolling Interests Related Terms

Biofrontera Net Income Including Noncontrolling Interests Historical Data

* Premium members only.

The historical data trend for Biofrontera's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera Net Income Including Noncontrolling Interests Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -37.71 -0.64 -20.13 -17.76 -10.54

Biofrontera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.20 -5.32 -6.65 5.64 -4.75
BFRI
44GF Score
Biofrontera Inc BFRI
Net Income Including Noncontrolling Interests is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income Including Noncontrolling Interests of $-11.09 Mil mean?
Biofrontera (BFRI) has a Net Income Including Noncontrolling Interests of $-11.09 Mil as of Mar. 2026.
Is Biofrontera's Net Income Including Noncontrolling Interests too high?
Biofrontera's current Net Income Including Noncontrolling Interests is $-11.09 Mil. Overall, Biofrontera has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Net Income Including Noncontrolling Interests compare to AKAN and CABR?
Biofrontera's Net Income Including Noncontrolling Interests of $-11.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income Including Noncontrolling Interests for a Drug Manufacturers company?
A good Net Income Including Noncontrolling Interests depends on the Drug Manufacturers industry context. However, Net Income Including Noncontrolling Interests should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income Including Noncontrolling Interests mean?
A high Net Income Including Noncontrolling Interests can signal that a stock is expensive relative to its fundamentals. Biofrontera's current Net Income Including Noncontrolling Interests is $-11.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera (BFRI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $0.99 — trading 83.6% above its estimated fair value. The current Net Income Including Noncontrolling Interests is $-11.09 Mil. Biofrontera's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income Including Noncontrolling Interests calculated?
Net Income Including Noncontrolling Interests is calculated from a company's financial statements. For Biofrontera (BFRI), the current Net Income Including Noncontrolling Interests is $-11.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera (BFRI) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of $0.99 is trading 83.6% above its estimated GF Value™ of $0.54. GuruFocus considers Biofrontera to be Significantly Overvalued.

Key valuation signals for BFRI:

  • Net Income Including Noncontrolling Interests: $-11.09 Mil
  • GF Value™: $0.54 vs. price of $0.99 (83.6% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
44GF Score

Get the complete analysis for BFRI

Net Income Including Noncontrolling Interests is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price
$0.54
GF Value